CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients

Although the introduction of tyrosine kinase inhibitors (TKIs) has improved overall survival of patients with chronic myeloid leukemia (CML), about half of the patients eventually relapse after cessation of TKIs. In contrast, the remainder of the patients maintain molecular remission without TKIs, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsushita, M, Ozawa, K, Suzuki, T, Nakamura, M, Nakano, N, Kanchi, S, Ichikawa, D, Matsuki, E, Sakurai, M, Karigane, D, Kasahara, H, Tsukamoto, N, Shimizu, T, Mori, T, Nakajima, H, Okamoto, S, Kawakami, Y, Hattori, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709753/
https://www.ncbi.nlm.nih.gov/pubmed/28862699
http://dx.doi.org/10.1038/bcj.2017.84

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709753/
https://www.ncbi.nlm.nih.gov/pubmed/28862699
http://dx.doi.org/10.1038/bcj.2017.84

Ejemplares similares